More recently, the presence of a systemic inflammatory response has been shown to impair the activity of cytochrome 3A (CYP3A4) in patients with advanced cancer patients (Rivory et al, 2002; Charles et al, 2006). The gene discussed is CYP3A4; the disease is cancer.